Canaccord Genuity Analysts Give Perrigo (PRGO) a $105.00 Price Target

Canaccord Genuity set a $105.00 price objective on Perrigo (NYSE:PRGO) in a research note published on Monday. The firm currently has a buy rating on the stock.

PRGO has been the subject of a number of other reports. Leerink Swann began coverage on shares of Perrigo in a research note on Tuesday, January 2nd. They issued a market perform rating and a $90.00 price objective for the company. Oppenheimer set a $98.00 price objective on shares of Perrigo and gave the company a buy rating in a research note on Monday, March 5th. Cantor Fitzgerald set a $107.00 price objective on shares of Perrigo and gave the company a buy rating in a research note on Friday, January 19th. JPMorgan Chase reiterated a neutral rating and issued a $83.00 price objective (up from $82.00) on shares of Perrigo in a research note on Monday, March 5th. Finally, Berenberg Bank began coverage on shares of Perrigo in a report on Thursday, February 1st. They issued a buy rating and a $117.00 price target for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $93.44.

Perrigo stock opened at $77.82 on Monday. Perrigo has a 1-year low of $63.68 and a 1-year high of $95.93. The company has a market capitalization of $11,335.70, a P/E ratio of 16.29, a price-to-earnings-growth ratio of 2.00 and a beta of 0.76. The company has a quick ratio of 1.40, a current ratio of 1.96 and a debt-to-equity ratio of 0.53.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Thursday, March 1st. The company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.03. Perrigo had a net margin of 2.42% and a return on equity of 11.54%. The business had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the business earned $1.24 EPS. Perrigo’s revenue was down 3.6% compared to the same quarter last year. sell-side analysts forecast that Perrigo will post 5.23 EPS for the current year.

In other Perrigo news, CEO Uwe Roehrhoff purchased 7,500 shares of the stock in a transaction on Monday, March 5th. The stock was acquired at an average cost of $81.85 per share, with a total value of $613,875.00. Following the completion of the purchase, the chief executive officer now directly owns 4,900 shares of the company’s stock, valued at approximately $401,065. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.90% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Dupont Capital Management Corp purchased a new position in shares of Perrigo in the fourth quarter valued at about $104,000. ARP Americas LP purchased a new position in shares of Perrigo in the fourth quarter valued at about $212,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Perrigo in the fourth quarter valued at about $213,000. Investors Research Corp purchased a new position in shares of Perrigo in the fourth quarter valued at about $214,000. Finally, V Wealth Management LLC purchased a new position in shares of Perrigo in the fourth quarter valued at about $214,000. Hedge funds and other institutional investors own 79.09% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://weekherald.com/2018/04/26/canaccord-genuity-analysts-give-perrigo-prgo-a-105-00-price-target.html.

About Perrigo

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.

Analyst Recommendations for Perrigo (NYSE:PRGO)

Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply